Browse Items · NEOMED Bibliography Database

Nosocomial (Health Care-Associated) Legionnaire's Disease.

Nosocomial Legionnaire's disease is most frequently associated with presence of the organism in hospital water systems. Patients are often susceptible as a result of age, underlying comorbidities, or immunosuppression. Prevention focuses on reducing…

Tags: *Cross Infection/diagnosis/epidemiology/prevention & control, *Disease Outbreaks, *Health care-associated, *Legionella, *Legionnaires' Disease/diagnosis/epidemiology/prevention & control, *Nosocomial, *Outbreaks, *Prevention, 2017, Abell Virginia, Agarwal Shanu, Department of Internal Medicine, File Thomas M Jr, Hospitals, Humans, Infectious disease clinics of North America, NEOMED College of Medicine, Water Microbiology

Optimizing Antimicrobial Utilization: Job of a Steward, or Time for a Pilot?...Bush LM, Kaye D. Optimizing antimicrobial utilization: job of a steward, or time for a pilot? Clin Infect Dis 2017; 65:1195

Pneumonia in older adults: reversing the trend.

Tags: 2005, 80 and over, Aged, Department of Internal Medicine, File T M Jr, File Thomas M Jr, Immunization – Trends, JAMA: Journal of the American Medical Association, NEOMED College of Medicine, Pneumonia – Epidemiology – In Old Age, Pneumonia – Risk Factors, Tan J S, Tan James S

Case studies of lower respiratory tract infections: community-acquired pneumonia.

Community-acquired pneumonia (CAP) is a common and potentially serious illness with significant human and economic costs to society. The recent collaborative statement from the Infectious Diseases Society of America (IDSA) and the American Thoracic…

Tags: 2010, Acute – Microbiology, Adult, Adult/microbiology, Aged, Anti-Bacterial Agents/*therapeutic use, Antibiotics – Therapeutic Use, Antitubercular Agents – Therapeutic Use, Antitubercular Agents/therapeutic use, Community-Acquired Infections – Diagnosis, Community-Acquired Infections – Drug Therapy, Community-Acquired Infections/diagnosis/drug therapy, Cough, Cough – Microbiology, Cough/microbiology/virology, Department of Internal Medicine, Diagnosis, Differential, Dyspnea, Fatal Outcome, Female, Fever – Microbiology, Fever/microbiology, File Thomas M Jr, Hemoptysis – Microbiology, Hemoptysis/microbiology, Human, Human – Complications, Human – Diagnosis, Human/complications/*diagnosis, Humans, Hypotension – Microbiology, Hypotension/microbiology, Influenza, Leukopenia – Microbiology, Leukopenia/microbiology, Male, Methicillin-Resistant Staphylococcus aureus, Methicillin-Resistant Staphylococcus aureus/*isolation & purification, Miliary/diagnosis/drug therapy, Multiple Organ Dysfunction Syndrome – Microbiology, Multiple Organ Failure/microbiology, Mycobacterium Tuberculosis, Mycobacterium tuberculosis/isolation & purification, NEOMED College of Medicine, Pneumonia – Diagnosis, Pneumonia – Drug Therapy, Pneumonia – Microbiology, Pneumonia – Therapy, Pneumonia/*diagnosis/*drug therapy/microbiology/therapy, Practice Guidelines, Practice Guidelines as Topic, Respiratory Distress Syndrome, Risk Factors, Severity of Illness Index, Severity of Illness Indices, Smoking, Smoking/adverse effects, Staphylococcal Infections – Diagnosis, Staphylococcal Infections – Drug Therapy, Staphylococcal Infections – Microbiology, Staphylococcal Infections – Therapy, Staphylococcal Infections/*diagnosis/*drug therapy/microbiology/therapy, The American journal of medicine, Tuberculosis, Tuberculosis – Diagnosis, Tuberculosis – Drug Therapy

New diagnostic tests for pneumonia: what is their role in clinical practice?

The utility of diagnostic studies to determine the etiologic agents of community-acquired pneumonia has been controversial in part because of the lack of rapid, accurate, easily performed, and cost-effective methods. Advancements in molecular testing…

Tags: 2011, Antigens, Bacterial/*diagnosis/metabolism, Bacterial/urine, Calcitonin/blood, Clinics in chest medicine, Community-Acquired Infections/*diagnosis/metabolism/*microbiology/virology, Department of Internal Medicine, File Thomas M Jr, Humans, NEOMED College of Medicine, Nucleic Acid Amplification Techniques, Pneumonia, Polymerase Chain Reaction, Protein Precursors/blood, Viral/*diagnosis/metabolism

The development of pharmacokinetically enhanced amoxicillin/clavulanate for the management of respiratory tract infections in adults.

Rising levels of resistance amongst the major respiratory pathogens have compromised empiric antimicrobial therapy. This, coupled with a recent lack in availability of novel classes of antibacterials, has led to a need for new approaches to combat…

Tags: 2007, Adult, Amoxicillin-Potassium Clavulanate Combination/*administration & dosage/pharmacokinetics/therapeutic use, Anti-Bacterial Agents/*administration & dosage/pharmacokinetics/therapeutic use, Bacteria/*drug effects/isolation & purification, Community-Acquired Infections/*drug therapy/microbiology, Department of Internal Medicine, File Thomas M Jr, Humans, International journal of antimicrobial agents, NEOMED College of Medicine, Pneumonia/drug therapy/microbiology, Respiratory Tract Infections/*drug therapy/microbiology, Sinusitis/drug therapy/microbiology

A new dosing paradigm: high-dose, short-course fluoroquinolone therapy for community-acquired pneumonia.

The goals of optimal antimicrobial therapy are to treat infection effectively, to improve the clinical condition of the patient, and to prevent the emergence of resistant bacterial strains. For ideal drug usage the World Health Organization…

Tags: 2003, Clinical cornerstone, Community-Acquired Infections/*drug therapy, Department of Internal Medicine, File Thomas M Jr, Fluoroquinolones/*administration & dosage/pharmacology/therapeutic use, Humans, NEOMED College of Medicine, Ofloxacin/administration & dosage/pharmacology/therapeutic use, Pneumococcal/*drug therapy, Pneumonia, Safety, Time Factors, Treatment Outcome

Appropriate use of antimicrobials for drug-resistant pneumonia: focus on the significance of beta-lactam-resistant Streptococcus pneumoniae.

The beta-lactam antibiotics (penicillins and cephalosporins) are commonly prescribed for the treatment of community-acquired pneumonia. However, Streptococcus pneumoniae, the most common etiologic agent of community-acquired pneumonia, has become…

Tags: *beta-Lactam Resistance, 2002, beta-Lactams/economics/*therapeutic use, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Contraindications, Department of Internal Medicine, File Thomas M Jr, Humans, NEOMED College of Medicine, Pneumococcal/*drug therapy/economics/pathology, Pneumonia, Practice Guidelines as Topic, Streptococcus pneumoniae/*drug effects/metabolism

Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia.

Streptococcus pneumoniae, the most important respiratory tract pathogen implicated in community-acquired pneumonia (CAP), is becoming increasingly resistant in vitro to the beta -lactams and macrolides, and fluoroquinolone resistance has been…

Tags: 2004, Anti-Infective Agents/*therapeutic use, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Community-Acquired Infections/*drug therapy/microbiology, Department of Internal Medicine, File Thomas M Jr, Humans, NEOMED College of Medicine, Pneumonia/*drug therapy/microbiology, Streptococcus pneumoniae/drug effects/isolation & purification, Treatment Outcome

Recommendations for treatment of hospital-acquired and ventilator-associated pneumonia: review of recent international guidelines.

Recently published guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia are reviewed for recommendations regarding diagnosis and antimicrobial therapy to assess the implications for development of future…

Tags: *Practice Guidelines as Topic, 2010, Anti-Bacterial Agents/*therapeutic use, Bacteria/drug effects/isolation & purification, Bacterial/diagnosis/*drug therapy, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Clinical Trials as Topic, Cross Infection/diagnosis/*drug therapy, Department of Internal Medicine, File Thomas M Jr, Hospitals, Humans, Microbial Sensitivity Tests, NEOMED College of Medicine, Pneumonia, Time Factors, Ventilator-Associated/diagnosis/*drug therapy

Community-associated methicillin-resistant Staphylococcus aureas: not only a cause of skin infections, also a new cause of pneumonia.

Tags: *Methicillin Resistance, 2005, Anti-Bacterial Agents/pharmacology, Bacterial/*epidemiology/*microbiology, Community-Acquired Infections, Current opinion in infectious diseases, Department of Internal Medicine, File Thomas M Jr, Humans, NEOMED College of Medicine, Pneumonia, Staphylococcal Infections/*epidemiology, Staphylococcus aureus/*drug effects

Solutions to the problem of bacterial resistance.

The recent increase in bacterial resistance has been, and continues to be, unmatched by drug discovery and development. The judicious use of antibacterials must be observed so as to contain bacterial resistance and maintain the utility of agents…

Tags: *Drug Resistance, *Practice Guidelines as Topic, 2005, Anti-Bacterial Agents/*therapeutic use, Bacterial, Department of Internal Medicine, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Prescriptions/standards, Drug Utilization, File Thomas M Jr, Humans, NEOMED College of Medicine, Professional Practice/*standards, Treatments in respiratory medicine, Unnecessary Procedures

Impact of community-acquired methicillin-resistant Staphylococcus aureus in the hospital setting.

The epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) is undergoing a transformation as isolates of this historically health care-associated pathogen are reported with increasing frequency in otherwise healthy community-dwelling…

Tags: 2007, Bacterial, Cleveland Clinic journal of medicine, Community-Acquired Infections/epidemiology/microbiology/*prevention & control, Cross Infection/epidemiology/microbiology/*prevention & control, Department of Internal Medicine, DNA, File Thomas M Jr, Hospitals, Humans, Infection Control, Methicillin Resistance/*genetics, NEOMED College of Medicine, Staphylococcal Infections/drug therapy/epidemiology/*prevention & control, Staphylococcus aureus/*drug effects/genetics

Another perspective: reducing the overtreatment of pneumonia.

Tags: *Diagnostic Errors, 2013, Age Factors, Anti-Bacterial Agents/therapeutic use, Cleveland Clinic journal of medicine, Comorbidity, Department of Internal Medicine, File Thomas M Jr, Humans, NEOMED College of Medicine, Pneumonia/*diagnosis/*drug therapy

[Clinical impact of appropriate use of antibiotic in hospital according to CARAT criteria].

In response to the overuse and misuse of antibiotics, leading to increasing bacterial resistance and the decreasing development of new antibiotics, the Council for Appropriate and Rational Antibiotic Therapy (an independent, interdisciplinary panel…

Evolution of amoxicillin/clavulanate in the treatment of adults with acute bacterial rhinosinusitis and community-acquired pneumonia in response to antimicrobial-resistance patterns.

Current treatment guidelines for community-acquired respiratory tract infections no longer depend solely on the characteristics of the patient and the clinical syndrome, but on those of the offending pathogen, including presence and level of…

Tags: 2004, Amoxicillin-Potassium Clavulanate Combination/*therapeutic use, Anti-Bacterial Agents/pharmacology, Bacteria/drug effects/isolation & purification, Bacterial, Benninger Michael S, Clinics in laboratory medicine, Combination/*therapeutic use, Community-Acquired Infections/drug therapy/microbiology, Department of Internal Medicine, Drug Resistance, Drug Therapy, File Thomas M Jr, Humans, Jacobs Michael R, Microbial Sensitivity Tests, NEOMED College of Medicine, Pneumonia/*drug therapy/microbiology, Sinusitis/*drug therapy/microbiology

Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcome assessment at an early time point.

BACKGROUND: Therapy directed against atypical pathogens in patients with community-acquired pneumonia (CAP) is often recommended. This post-hoc analysis evaluated the effect of addition of a macrolide to ceftaroline fosamil or ceftriaxone treatment…

Tags: 2017, 80 and over, Adult, Aged, Anti-Bacterial Agents/adverse effects/*therapeutic use, Atypical pathogen, Bacterial/*drug therapy, Ceftaroline fosamil, Ceftriaxone/adverse effects/*therapeutic use, Cephalosporins/adverse effects/*therapeutic use, Chlamydial Pneumonia, Chlamydophila pneumoniae, Clinical Trials, Combination/adverse effects/methods, Community-Acquired Infections/*drug therapy, Community-acquired pneumonia, Department of Internal Medicine, Double-Blind Method, Drug Therapy, Eckburg Paul B, Female, File Thomas M Jr, Friedland H David, Humans, International journal of antimicrobial agents, Legionella pneumophila, Llorens Lily, Macrolide, Macrolides/adverse effects/*therapeutic use, Male, Middle Aged, Mycoplasma, Mycoplasma pneumoniae, NEOMED College of Medicine, Phase III as Topic, Pneumonia, Randomized Controlled Trials as Topic, Talbot George H, Time Factors, Treatment Outcome

Is the risk of serious infections increased in patients with RA who receive treatment with antirheumatic drugs?

Tags: 2008, Department of Internal Medicine, File Elizabeth A, File Thomas M Jr, Nature clinical practice. Rheumatology, NEOMED College of Medicine

Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia.

Empiric antimicrobial prescribing for community-acquired pneumonia remains a challenge, despite the availability of treatment guidelines. A number of key differences exist between North American and European guidelines, mainly in the outpatient…

Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin/clavulanate.

The efficacy of a new pharmacokinetically enhanced formulation of amoxycillin/clavulanate (AMX/CA) 2000/125 mg, twice daily, designed to provide adequate levels of amoxycillin over the 12-h dosing interval to eradicate penicillin-resistant…

Tags: *Treatment Outcome, 2002, 80 and over, Adolescent, Adult, Aged, Amoxicillin-Potassium Clavulanate Combination/administration & dosage/*pharmacokinetics/pharmacology/*therapeutic use, Amoxicillin/adverse effects/therapeutic use, Bacterial, Bacterial/drug therapy/immunology, Bronchitis/drug therapy/microbiology, Combination/adverse effects/*therapeutic use, Department of Internal Medicine, Double-Blind Method, Drug Administration Schedule, Drug Resistance, Drug Therapy, Female, File Thomas M Jr, Follow-Up Studies, Humans, International journal of antimicrobial agents, Jacobs Michael R, Male, Microbial Sensitivity Tests, Middle Aged, Multicenter Studies as Topic, NEOMED College of Medicine, Pneumonia, Poole Michael D, Respiratory Tract Infections/*drug therapy/metabolism/microbiology, Streptococcal Infections/*drug therapy/metabolism/microbiology, Streptococcus pneumoniae/*drug effects, Wynne Brian

FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.

OBJECTIVES: Ceftaroline, the active form of the prodrug ceftaroline fosamil, is a novel cephalosporin with bactericidal activity against important pathogens associated with community-acquired pneumonia (CAP), including Streptococcus pneumoniae and…

Tags: 2011, 80 and over, Aged, Bacteria, Bacteria/isolation & purification, Bacterial – Drug Therapy, Bacterial/*drug therapy, Ceftriaxone – Administration and Dosage, Ceftriaxone – Adverse Effects, Ceftriaxone/administration & dosage/adverse effects, Cephalosporins – Administration and Dosage, Cephalosporins – Adverse Effects, Cephalosporins/*administration & dosage/*adverse effects, Community-Acquired Infections – Drug Therapy, Community-Acquired Infections/*drug therapy, Critchley Ian A, Department of Internal Medicine, Double-Blind Method, Double-Blind Studies, Eckburg Paul B, Female, File Thomas M Jr, Friedland H David, Human, Humans, Infusions, Intravenous, Lee Jon, Llorens Lily, Low Donald E, Male, Middle Age, Middle Aged, NEOMED College of Medicine, Pneumonia, RANDOMIZED controlled trials, Talbot George H, The Journal of antimicrobial chemotherapy, Thye Dirk A, Treatment Outcome, Treatment Outcomes

Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia.

BACKGROUND: Ceftaroline, the active form of ceftaroline fosamil, is a broad-spectrum cephalosporin with bactericidal activity against pathogens causing community-acquired pneumonia (CAP), including Streptococcus pneumoniae. Ceftaroline was evaluated…

Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.

OBJECTIVES: Short-course therapy has been advocated for the treatment of community-acquired pneumonia (CAP). We compared the efficacy and safety of 5 and 7 day courses of gemifloxacin for outpatient treatment of mild-moderate CAP. PATIENTS AND…

Does empiric therapy for atypical pathogens improve outcomes for patients with CAP?

The present controversy regarding the need to cover atypical pathogens in the empiric therapy of community-acquired pneumonia is related to several issues, including the relevance of terminology, imprecise diagnostic methods, and perceived…

Tags: 2013, Anti-Bacterial Agents/*therapeutic use, Antibiotic Prophylaxis, Antibiotics – Therapeutic Use, Clinical Trials, Clinical Trials as Topic, Community-Acquired Infections – Drug Therapy, Community-Acquired Infections – Microbiology, Community-Acquired Infections/drug therapy/microbiology, Department of Internal Medicine, File Thomas M Jr, Humans, Infectious disease clinics of North America, Marrie Thomas J, NEOMED College of Medicine, Pneumonia – Drug Therapy, Pneumonia – Microbiology, Pneumonia/*drug therapy/microbiology

Burden of community-acquired pneumonia in North American adults.

To determine the burden of community-acquired pneumonia (CAP) affecting adults in North America, a comprehensive literature review was conducted to examine the incidence, morbidity and mortality, etiology, antibiotic resistance, and economic impact…

Tags: 2010, Adult, Bacterial – Economics, Bacterial – Epidemiology, Bacterial – Microbiology, Bacterial – Mortality, Bacterial – Prevention and Control, Bacterial/economics/*epidemiology/microbiology/prevention & control, Community-Acquired Infections – Economics, Community-Acquired Infections – Epidemiology, Community-Acquired Infections – Microbiology, Community-Acquired Infections – Prevention and Control, Community-Acquired Infections/economics/epidemiology/microbiology/prevention & control, Cost of Illness, Department of Internal Medicine, Economic Aspects of Illness, File Thomas M Jr, Health Care Costs, Health Status Indicators, Hospitalization – Economics, Hospitalization – Statistics and Numerical Data, Hospitalization/economics/statistics & numerical data, Human, Humans, Incidence, Length of Stay – Statistics and Numerical Data, Length of Stay/statistics & numerical data, Marrie Thomas J, NEOMED College of Medicine, North America, North America/epidemiology, Pneumococcal Vaccine, Pneumococcal Vaccines, Pneumococcal/economics/epidemiology/mortality/prevention & control, Pneumonia, Postgraduate medicine, Risk Factors, Streptococcus, Streptococcus pneumoniae

Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia.

OBJECTIVE: To evaluate the time to symptom resolution and i.v.-to-p.o. transition in community-acquired pneumonia (CAP) patients treated with 750 mg or 500 mg levofloxacin. RESEARCH DESIGN: A retrospective, subset analysis of a multicenter,…

A disease model descriptive of progression between chronic obstructive pulmonary disease exacerbations and community-acquired pneumonia: roles for underlying lung disease and the pharmacokinetics/pharmacodynamics of the antibiotic.

Patients with chronic obstructive pulmonary disease (COPD) may progress to community-acquired pneumonia (CAP), but there has been no formal study of the factors responsible. We studied the influence of severity of underlying lung disease, pathogen…

Tags: *Anti-Bacterial Agents/pharmacokinetics/therapeutic use, *Community-Acquired Infections/drug therapy/microbiology/physiopathology/prevention & control, *Models, *Pneumonia, 2009, Adelman Martin H, Aged, Area Under Curve, Bacterial/drug therapy/microbiology/physiopathology/prevention & control, Biological, Bronchitis, Chronic Obstructive/drug therapy/microbiology/*physiopathology, Chronic/drug therapy/microbiology/physiopathology, Department of Internal Medicine, Disease Progression, Female, File Thomas M Jr, Humans, International journal of antimicrobial agents, Klugman Keith P, Lavin Bruce, Lung Diseases/complications/drug therapy/microbiology, Lung/microbiology, Male, Microbial Sensitivity Tests, Middle Aged, Monte Scott V, NEOMED College of Medicine, Paladino Joseph A, Pneumococcal/drug therapy/microbiology/physiopathology/prevention & control, Pneumonia, Pulmonary Disease, Schentag Jerome J, Severity of Illness Index, Singer Mendel E, Streptococcus pneumoniae/*drug effects, Yu Victor L

SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia.

BACKGROUND: Solithromycin, a novel macrolide antibiotic with both intravenous and oral formulations dosed once daily, has completed 2 global phase 3 trials for treatment of community-acquired bacterial pneumonia. METHODS: A total of 863 adults with…

Tags: *clinical trial, *Community-acquired, *Pneumonia, *solithromycin, *Streptococcus pneumoniae, 2016, 80 and over, Administration, Adult, Aged, Anti-Bacterial Agents/*administration & dosage/adverse effects, Bacterial, Bacterial/diagnosis/*drug therapy/*microbiology, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Community-Acquired Infections/diagnosis/*drug therapy/*microbiology, Comorbidity, Das Anita F, Department of Internal Medicine, Drug Resistance, Female, Fernandes Prabhavathi, File Thomas M Jr, Fluoroquinolones/*administration & dosage/adverse effects, Gonong Joven Roque V, Humans, Intravenous, Jamieson Brian D, Keedy Kara, Macrolides/*administration & dosage/adverse effects, Male, Microbial Sensitivity Tests, Middle Aged, Moxifloxacin, NEOMED College of Medicine, Oldach David, Oral, Pneumonia, Rewerska Barbara, Sheets Amanda, Taylor David, Treatment Outcome, Triazoles/*administration & dosage/adverse effects, Vucinic-Mihailovic Violeta

What can we learn from the time course of untreated and partially treated community-onset Streptococcus pneumoniae pneumonia? A clinical perspective on superiority and noninferiority trial designs for mild community-acquired pneumonia.

There are no well-designed placebo-controlled clinical trials in the recent era that precisely define the magnitude of the drug effect of antimicrobial therapy for mild community-acquired pneumonia (CAP). However, there is evidence that ineffective…

Tags: *Research Design, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Community-Acquired Infections/*drug therapy/microbiology, Department of Internal Medicine, Disease Progression, File Thomas M Jr, Humans, NEOMED College of Medicine, Pneumococcal/*drug therapy/microbiology, Pneumonia, Randomized Controlled Trials as Topic/*methods, Schentag Jerome J, Streptococcus pneumoniae/*isolation & purification, Time Factors, Treatment Outcome

Strategies for improving antimicrobial use and the role of antimicrobial stewardship programs.

International guidelines for the treatment of community-acquired pneumonia in adults: the role of macrolides.

The significance of community-acquired pneumonia (CAP) has led to the publication of guidelines from numerous international organisations. Because the macrolide class of antimicrobials is active against most of the key pathogens associated with CAP,…

Severe acute respiratory syndrome: pertinent clinical characteristics and therapy.

Severe acute respiratory syndrome (SARS) is a newly emerged infection that is caused by a previously unrecognized virus - a novel coronavirus designated as

Tags: *Severe Acute Respiratory Syndrome/*diagnosis/epidemiology/*therapy/transmission, 2005, Algorithms, Department of Internal Medicine, File Thomas M Jr, Humans, Infection Control, NEOMED College of Medicine, Treatments in respiratory medicine, Tsang Kenneth W T

Summary of ceftaroline fosamil clinical trial studies and clinical safety.

In October 2010, the new cephalosporin, ceftaroline fosamil, was approved by the US Food and Drug Administration for therapy of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSIs). The active…

Tags: 2012, Anti-Bacterial Agents/adverse effects/*therapeutic use, Bacterial/drug therapy, Cephalosporins/adverse effects/*therapeutic use, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Clinical Trials as Topic, Department of Internal Medicine, File Thomas M Jr, Humans, NEOMED College of Medicine, Pneumonia, Staphylococcal Skin Infections/drug therapy, Stein Gary E, Wilcox Mark H

Prevalence of Inappropriate Antibiotic Prescriptions Among US Ambulatory Care Visits, 2010-2011.

IMPORTANCE: The National Action Plan for Combating Antibiotic-Resistant Bacteria set a goal of reducing inappropriate outpatient antibiotic use by 50% by 2020, but the extent of inappropriate outpatient antibiotic use is unknown. OBJECTIVE: To…

Tags: 2016, Adolescence, Adolescent, Adult, Aged, Ambulatory Care – Statistics and Numerical Data, Ambulatory Care/*statistics & numerical data, Anti-Bacterial Agents/*therapeutic use, Antibiotics – Therapeutic Use, Bartoces Monina, Child, Department of Internal Medicine, Enns Eva A, Female, File Thomas M Jr, Finkelstein Jonathan A, Fleming-Dutra Katherine E, Gerber Jeffrey S, Health Care Surveys, Hersh Adam L, Hicks Lauri A, Human, Humans, Hyun David Y, Inappropriate Prescribing – Statistics and Numerical Data, Inappropriate Prescribing/*statistics & numerical data, Infant, JAMA, Linder Jeffrey A, Lynfield Ruth, Male, Margolis David J, May Larissa S, Merenstein Daniel, Metlay Joshua P, Middle Age, Middle Aged, NEOMED College of Medicine, Newborn, Newland Jason G, Otitis Media, Otitis Media – Drug Therapy, Pharyngitis – Drug Therapy, Pharyngitis/drug therapy, Physicians'/*statistics & numerical data, Piccirillo Jay F, Practice Patterns, Preschool, Prevalence, Respiratory Tract Infections – Drug Therapy, Respiratory Tract Infections/drug therapy, Roberts Rebecca M, Sanchez Guillermo V, Shapiro Daniel J, Suda Katie J, Suppurative/*drug therapy, Surveys, Thomas Ann, United States, Woo Teri Moser, Zetts Rachel M

Diagnosis and Treatment of Clostridium difficile Infection (CDI).

Early and accurate diagnosis is essential for optimal treatment of individuals with Clostridium difficile infection (CDI) and for implementation of effective infection control procedures. The decision about which diagnostic test to use is an…

Tags: 2016, CDI, Clostridium difficile, Department of Internal Medicine, diagnostic test, File Thomas M Jr, Gerding Dale N, Infectious diseases in clinical practice (Baltimore, Md.), McDonald L Clifford, NEOMED College of Medicine, Treatment

The Evolving Role of Antimicrobial Stewardship in Management of Multidrug Resistant Infections.

This article summarizes the current literature describing how antimicrobial stewardship interventions impact antimicrobial resistance. Discussion includes why we need stewardship, how to collaborate with team members, and the evidence of…

Tags: *Anti-Bacterial Agents/administration & dosage/therapeutic use, *Antibiotics, *Antimicrobial resistance, *Antimicrobial stewardship, *Drug Resistance, *Medication Therapy Management, 2016, Bacterial, Bacterial Infections/drug therapy, Department of Internal Medicine, File Thomas M Jr, Goff Debra A, Humans, Infectious disease clinics of North America, Multiple, NEOMED College of Medicine

Approaches to Modifying the Behavior of Clinicians Who Are Noncompliant With Antimicrobial Stewardship Program Guidelines.

Antimicrobial stewardship programs (ASPs) are a key national initiative to promote appropriate use of antibiotics and to reduce the burden of resistance. The dilemma of managing the outlier physician is especially complex. We outline strategies to…

Tags: *Ambulatory Care, *Hospitalization, 2003, American journal of respiratory medicine : drugs, devices, and other interventions, Anti-Bacterial Agents/*administration & dosage, Bacterial/*therapy, Community-Acquired Infections/therapy, Department of Internal Medicine, File Thomas M Jr, Humans, NEOMED College of Medicine, Pneumonia, Tan James S

Browse Items (42 total)